1A) Time to Progression (TTP) on first line Endocrine-based Therapy in patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.
1B) TTP on first exposure to Chemotherapy among patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.
1C) TTP on first line Endocrine Therapy in combination with CDK 4/6 inhibitor among patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.
1D) TTP on first exposure to Endocrine Therapy in combination with mTOR inhibitor among patients with metastatic HR+/HER2− breast cancer, stratified by FGFR1 amplification status.